Hekmatdoost A - Search Results

1

Effects of supplementation with main coffee components including caffeine and/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled, clinical trial.

Mansour A, Mohajeri-Tehrani MR, Samadi M, Qorbani M, Merat S, Adibi H, Poustchi H, Hekmatdoost A. Mansour A, et al. Among authors: hekmatdoost a. Nutr J. 2021 Apr 10;20(1):35. doi: 10.1186/s12937-021-00694-5. Nutr J. 2021. PMID: 33838673 Free PMC article. Clinical Trial.

2

Effect of nutrition intervention on non-communicable disease risk factors among Tehranian adults: Tehran Lipid and Glucose Study.

Mirmiran P, Ramezankhani A, Hekmatdoost A, Azizi F. Mirmiran P, et al. Among authors: hekmatdoost a. Ann Nutr Metab. 2008;52(2):91-5. doi: 10.1159/000121364. Epub 2008 Mar 18. Ann Nutr Metab. 2008. PMID: 18349527

3

Dietary fatty acid composition and metabolic syndrome in Tehranian adults.

Hekmatdoost A, Mirmiran P, Hosseini-Esfahani F, Azizi F. Hekmatdoost A, et al. Nutrition. 2011 Oct;27(10):1002-7. doi: 10.1016/j.nut.2010.11.004. Nutrition. 2011. PMID: 21907897

4

Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study.

Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Eslamparast T, et al. Among authors: hekmatdoost a. Am J Clin Nutr. 2014 Mar;99(3):535-42. doi: 10.3945/ajcn.113.068890. Epub 2014 Jan 8. Am J Clin Nutr. 2014. PMID: 24401715 Free article. Clinical Trial.

5

Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients.

Askari F, Rashidkhani B, Hekmatdoost A. Askari F, et al. Among authors: hekmatdoost a. Nutr Res. 2014 Feb;34(2):143-8. doi: 10.1016/j.nutres.2013.11.005. Epub 2013 Dec 6. Nutr Res. 2014. PMID: 24461315 Clinical Trial.

6

Probiotics and Nonalcoholic Fatty liver Disease.

Eslamparast T, Eghtesad S, Hekmatdoost A, Poustchi H. Eslamparast T, et al. Among authors: hekmatdoost a. Middle East J Dig Dis. 2013 Jul;5(3):129-36. Middle East J Dig Dis. 2013. PMID: 24829682 Free PMC article. Review.

7

Effects of synbiotic supplementation on insulin resistance in subjects with the metabolic syndrome: a randomised, double-blind, placebo-controlled pilot study.

Eslamparast T, Zamani F, Hekmatdoost A, Sharafkhah M, Eghtesad S, Malekzadeh R, Poustchi H. Eslamparast T, et al. Among authors: hekmatdoost a. Br J Nutr. 2014 Aug 14;112(3):438-45. doi: 10.1017/S0007114514000919. Epub 2014 May 22. Br J Nutr. 2014. PMID: 24848793 Clinical Trial.

8

Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.

Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. Faghihzadeh F, et al. Among authors: hekmatdoost a. Nutr Res. 2014 Oct;34(10):837-43. doi: 10.1016/j.nutres.2014.09.005. Epub 2014 Sep 23. Nutr Res. 2014. PMID: 25311610 Clinical Trial.

9

Systematic review of zinc biomarkers and esophageal cancer risk.

Hashemian M, Hekmatdoost A, Poustchi H, Mohammadi Nasrabadi F, Abnet CC, Malekzadeh R. Hashemian M, et al. Among authors: hekmatdoost a. Middle East J Dig Dis. 2014 Oct;6(4):177-85. Middle East J Dig Dis. 2014. PMID: 25349680 Free PMC article. Review.

10

Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease.

Eslamparast T, Eghtesad S, Poustchi H, Hekmatdoost A. Eslamparast T, et al. Among authors: hekmatdoost a. World J Hepatol. 2015 Feb 27;7(2):204-12. doi: 10.4254/wjh.v7.i2.204. World J Hepatol. 2015. PMID: 25729475 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

264 results

Search Page